Welcome to our dedicated page for Tff Pharmaceuticals news (Ticker: TFFP), a resource for investors and traders seeking the latest updates and insights on Tff Pharmaceuticals stock.
TFF Pharmaceuticals, Inc. (TFFP) has been described in its public communications as a clinical-stage biopharmaceutical company built around its proprietary Thin Film Freezing (TFF) technology platform. Over time, the company has issued news covering its inhaled dry powder product candidates, collaborations with academic and government partners, and later, significant corporate developments related to winding down operations and delisting from Nasdaq.
Earlier news from TFF Pharmaceuticals has focused on the progress of its TFF-based pipeline. This includes updates on tacrolimus inhalation powder (TFF TAC) for the prevention of lung transplant rejection, where the company has reported Phase 2 clinical data on safety, pharmacokinetics, biomarker outcomes, and patient enrollment. Additional releases have highlighted preclinical data for TFF-formulated influenza vaccine candidates and work on inhaled or intranasal dry powder formulations designed to address respiratory viral infections, including influenza and COVID, often in collaboration with institutions such as Emory University and Cleveland Clinic and with support from U.S. government agencies.
News items have also described the broader capabilities of the Thin Film Freezing platform, including its application to vaccines, small and large molecules, and biologics, and its potential to create temperature-stable dry powders suitable for inhalation or topical delivery. Corporate updates have included financial results, regulatory interactions with the U.S. Food and Drug Administration regarding the TFF TAC program, and the engagement of advisors to explore partnership and licensing opportunities.
More recent announcements mark a shift in focus, with TFF Pharmaceuticals disclosing the termination of its employees, a decision to wind down operations, and plans for liquidation and dissolution. The company has also announced its intent to voluntarily delist its common stock from the Nasdaq Capital Market, stating that this step is being taken in connection with the planned liquidation. This news page provides a record of both the scientific and clinical developments associated with the TFF platform and the subsequent corporate decisions affecting the company’s trading status and future.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.